Castle Biosciences (CSTL) Equity Ratio (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Equity Ratio data on file, last reported at 0.84 in Q1 2026.

• Quarterly Equity Ratio fell 4.02% year-over-year to 0.84 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.84 (down 4.02% YoY) and the FY2025 annual result came in at 0.81, down 5.15% from the prior year.
• Equity Ratio climbed to 0.84 in Q1 2026 per CSTL's latest filing, from 0.81 in the prior quarter.
• The five-year high for Equity Ratio was 0.92 in Q2 2022, with the low at 0.81 in Q4 2025.
• Average Equity Ratio over 5 years is 0.87, with a median of 0.88 recorded in 2025.
• Year-over-year, Equity Ratio dropped 6.6% in 2022 and rose 0.91% in 2023.
• Castle Biosciences' Equity Ratio stood at 0.89 in 2022, then slipped by 3.27% to 0.86 in 2023, then slipped by 0.58% to 0.86 in 2024, then slipped by 5.15% to 0.81 in 2025, then increased by 3.49% to 0.84 in 2026.
• Business Quant data shows CSTL's Equity Ratio at 0.84 in Q1 2026, 0.81 in Q4 2025, and 0.83 in Q3 2025.